• Thursday, April 4, 2019 @ 1:15 pm

InterAx Biotech AG announced today that it has entered an agreement with Lundbeck A/S to enable the in-depth characterization of drug candidates using the proprietary InterAx systems biology platform. InterAx and Lundbeck will combine their expertise in the characterization of drug candidates for an undisclosed target. “We are delighted to assist Lundbeck in their quest to identify compounds with superior biological properties for their target receptor with our unique technology”, says Maria Waldhoer, CSO at InterAx. Financial terms of the partnership were not disclosed.

You may also be interested in